Molecular Hydrogen Affords Similar Neuroprotection to Therapeutic Hypothermia in a Porcine Model of Neonatal Hypoxic-Ischemic Encephalopathy.
Emma Balog, Gábor Remzső, Valéria Tóth-Szűki, Éva Rózsa, Viktória Kovács, Ferenc Domoki · Antioxidants (Basel, Switzerland) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, tH eliminated post-asphyxia seizures and improved VEP latency, while H₂ delayed seizure onset and increased quantitative EEG markers of signal complexity. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas was evaluated in this publication and summarizes the source-grounded findings below. TH eliminated post-asphyxia seizures and improved VEP latency, while H₂ delayed seizure onset and increased quantitative EEG markers of signal complexity.
What the Researchers Studied
The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 5 µM H₂ (≈0.01 mg/L). TH eliminated post-asphyxia seizures and improved VEP latency, while H₂ delayed seizure onset and increased quantitative EEG markers of signal complexity. Therapeutic effects of H₂ were noted in adult ischemic stroke and subarachnoid hemorrhage models too, with hydrogen inhalation or hydrogen-rich solution ameliorating oxidative damage, inhibiting blood–brain barrier breakdown, and improving neurological function [ 24, 25, 26 ].
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 5 µM H₂ (≈0.01 mg/L).
Limitations and Safety
Reported limitations: A clear limitation of the present study is that sham-control groups were not included; however, the present findings showing minimal neuronal damage in both treated groups suggest that TH or H₂ treatment alone, in the absence of asphyxia, would not have likely compromised the neuronal viability as well. Safety information: Given its favorable safety profile and preclinical evidence of neuroprotection, H₂ may serve as a valuable pharmacological adjunct or as monotherapy in cases where TH is contraindicated within clinical settings [ 34, 35 ].
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.